{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:00:44Z","timestamp":1783602044678,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ashok & Ingrid Sarnaik Endowment for Resident and Fellow Research"},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA022453"],"award-info":[{"award-number":["P30 CA022453"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Decerchio\/Guisewite Family, Justin\u2019s Gift, Elana Fund, Ginopolis\/Karmanos Endowment, Ring Screw Textron Endowed Chair for Pediatric Cancer Research"},{"name":"The Children\u2019s Foundation, U Can Cer Vive Foundation, and Kids Without Cancer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>About 25% of patients with acute myeloid leukemia (AML) harbor FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations and their prognosis remains poor. Gilteritinib is a FLT3 inhibitor approved by the US FDA for use in adult FLT3-mutated relapsed or refractory AML patients. Monotherapy, while efficacious, shows short-lived responses, highlighting the need for combination therapies. Here we show that gilteritinib and CUDC-907, a dual inhibitor of PI3K and histone deacetylases, synergistically induce apoptosis in FLT3-ITD AML cell lines and primary patient samples and have striking in vivo efficacy. Upregulation of FLT3 and activation of ERK are mechanisms of resistance to gilteritinib, while activation of JAK2\/STAT5 is a mechanism of resistance to CUDC-907. Gilteritinib and CUDC-907 reciprocally overcome these mechanisms of resistance. In addition, the combined treatment results in cooperative downregulation of cellular metabolites and persisting antileukemic effects. CUDC-907 plus gilteritinib shows synergistic antileukemic activity against FLT3-ITD AML in vitro and in vivo, demonstrating strong translational therapeutic potential.<\/jats:p>","DOI":"10.1038\/s41408-021-00502-7","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T12:03:24Z","timestamp":1623067404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML"],"prefix":"10.1038","volume":"11","author":[{"given":"Xinan","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Polin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juiwanna","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijana H.","family":"Dzinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-5778","authenticated-orcid":false,"given":"Guan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-3235","authenticated-orcid":false,"given":"Jeffrey W.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-716X","authenticated-orcid":false,"given":"Yubin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"502_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J Clin. 71, 7\u201333 (2021).","journal-title":"CA Cancer J Clin."},{"key":"502_CR2","doi-asserted-by":"publisher","first-page":"5980","DOI":"10.1182\/blood-2012-02-392506","volume":"119","author":"JE Rubnitz","year":"2012","unstructured":"Rubnitz, J. E. How I treat pediatric acute myeloid leukemia. Blood. 119, 5980\u20135988 (2012).","journal-title":"Blood."},{"key":"502_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7\u201330 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"502_CR4","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","volume":"17","author":"M Levis","year":"2003","unstructured":"Levis, M. & Small, D. FLT3: ITDoes matter in leukemia. Leukemia 17, 1738\u20131752 (2003).","journal-title":"Leukemia"},{"key":"502_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1182\/blood.V97.1.89","volume":"97","author":"S Meshinchi","year":"2001","unstructured":"Meshinchi, S. et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97, 89\u201394 (2001).","journal-title":"Blood"},{"key":"502_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1042\/CS20110411","volume":"122","author":"VA Korshunov","year":"2012","unstructured":"Korshunov, V. A. Axl-dependent signalling: a clinical update. Clin. Sci. 122, 361\u2013368 (2012).","journal-title":"Clin. Sci."},{"key":"502_CR7","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-15-1458","volume":"22","author":"M Scaltriti","year":"2016","unstructured":"Scaltriti, M., Elkabets, M. & Baselga, J. Molecular pathways: AXL, a membrane receptor mediator of resistance to therapy. Clin. Cancer Res. 22, 1313\u20131317 (2016).","journal-title":"Clin. Cancer Res."},{"key":"502_CR8","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood-2013-03-491431","volume":"122","author":"I Ben-Batalla","year":"2013","unstructured":"Ben-Batalla, I. et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood 122, 2443\u20132452 (2013).","journal-title":"Blood"},{"key":"502_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","volume":"129","author":"LY Lee","year":"2017","unstructured":"Lee, L. Y. et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood 129, 257\u2013260 (2017).","journal-title":"Blood"},{"key":"502_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","volume":"18","author":"AE Perl","year":"2017","unstructured":"Perl, A. E. et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 18, 1061\u20131075 (2017).","journal-title":"Lancet Oncol."},{"key":"502_CR11","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.2217\/fon-2017-0582","volume":"14","author":"CM Gorcea","year":"2018","unstructured":"Gorcea, C. M., Burthem, J. & Tholouli, E. ASP2215 in the treatment of relapsed\/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial. Future Oncol. 14, 1995\u20132004 (2018).","journal-title":"Future Oncol."},{"key":"502_CR12","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl, A. E. et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. New Engl. J. Med. 381, 1728\u20131740 (2019).","journal-title":"New Engl. J. Med."},{"key":"502_CR13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","volume":"16","author":"M Larrosa-Garcia","year":"2017","unstructured":"Larrosa-Garcia, M. & Baer, M. R. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol. Cancer Ther. 16, 991\u20131001 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"502_CR14","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.3324\/haematol.2018.201343","volume":"104","author":"X Li","year":"2019","unstructured":"Li, X. et al. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia. Haematologica 104, 2225\u20132240 (2019).","journal-title":"Haematologica"},{"key":"502_CR15","first-page":"13","volume":"290","author":"CC Uphoff","year":"2005","unstructured":"Uphoff, C. C. & Drexler, H. G. Detection of mycoplasma contaminations. Methods Mol. Biol. 290, 13\u201323 (2005).","journal-title":"Methods Mol. Biol."},{"key":"502_CR16","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/leu.2014.72","volume":"28","author":"X Niu","year":"2014","unstructured":"Niu, X. et al. Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia 28, 1557\u20131560 (2014).","journal-title":"Leukemia"},{"key":"502_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep41950","volume":"7","author":"J Ma","year":"2017","unstructured":"Ma, J. et al. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells. Sci Rep. 7, 41950 (2017).","journal-title":"Sci Rep."},{"key":"502_CR18","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1182\/blood.V87.8.3395.bloodjournal8783395","volume":"87","author":"JW Taub","year":"1996","unstructured":"Taub, J. W. et al. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down Syndrome cells: a contributing factor to the superior event free survival of Down Syndrome children with acute myeloid leukemia. Blood 87, 3395\u20133403 (1996).","journal-title":"Blood"},{"key":"502_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0145-2126(96)00132-4","volume":"21","author":"H Quentmeier","year":"1997","unstructured":"Quentmeier, H., Zaborski, M. & Drexler, H. G. The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines. Leukemia Res. 21, 343\u2013350 (1997).","journal-title":"Leukemia Res."},{"key":"502_CR20","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.1158\/1078-0432.CCR-10-1707","volume":"16","author":"C Xie","year":"2010","unstructured":"Xie, C. et al. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res. 16, 5499\u20135510 (2010).","journal-title":"Clin Cancer Res."},{"key":"502_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681 (2006).","journal-title":"Pharmacol. Rev."},{"key":"502_CR22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/jnci\/dji026","volume":"97","author":"Y Ge","year":"2005","unstructured":"Ge, Y. et al. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J. Natl Cancer Inst. 97, 226\u2013231 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"502_CR23","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2005-06-2219","volume":"107","author":"Y Ge","year":"2006","unstructured":"Ge, Y. et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 107, 1570\u20131581 (2006).","journal-title":"Blood"},{"key":"502_CR24","doi-asserted-by":"publisher","first-page":"e79106","DOI":"10.1371\/journal.pone.0079106","volume":"8","author":"C Xie","year":"2013","unstructured":"Xie, C. et al. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PLoS ONE 8, e79106 (2013).","journal-title":"PLoS ONE"},{"key":"502_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"502_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bcp.2017.11.022","volume":"148","author":"Y Su","year":"2018","unstructured":"Su, Y. et al. Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem. Pharmacol. 148, 13\u201326 (2018).","journal-title":"Biochem. Pharmacol."},{"key":"502_CR27","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1111\/jcmm.13886","volume":"22","author":"DA Luedtke","year":"2018","unstructured":"Luedtke, D. A. et al. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1. J. Cell Mol. Med. 22, 6099\u20136111 (2018).","journal-title":"J. Cell Mol. Med."},{"key":"502_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jcph.1275","volume":"59","author":"X Bao","year":"2019","unstructured":"Bao, X., Wu, J., Kim, S., LoRusso, P. & Li, J. Pharmacometabolomics reveals irinotecan mechanism of action in cancer patients. J. Clin. Pharmacol. 59, 20\u201334 (2019).","journal-title":"J. Clin. Pharmacol."},{"key":"502_CR29","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","volume":"25","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia. Clin. Cancer Res. 25, 6815\u20136826 (2019).","journal-title":"Clin. Cancer Res."},{"key":"502_CR30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1021\/jm1011319","volume":"54","author":"S IoanIoannidis","year":"2011","unstructured":"IoanIoannidis, S. et al. Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak\/Stat pathway. J. Med. Chem. 54, 262\u2013276 (2011).","journal-title":"J. Med. Chem."},{"key":"502_CR31","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1038\/sj.onc.1207692","volume":"23","author":"AM Domina","year":"2004","unstructured":"Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R. & Craig, R. W. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23, 5301\u20135315 (2004).","journal-title":"Oncogene"},{"key":"502_CR32","doi-asserted-by":"publisher","first-page":"18811","DOI":"10.1074\/jbc.M301010200","volume":"278","author":"R Ley","year":"2003","unstructured":"Ley, R., Balmanno, K., Hadfield, K., Weston, C. & Cook, S. J. Activation of the ERK1\/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J. Biol. Chem. 278, 18811\u201318816 (2003).","journal-title":"J. Biol. Chem."},{"key":"502_CR33","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","volume":"22","author":"F Luciano","year":"2003","unstructured":"Luciano, F. et al. Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22, 6785\u20136793 (2003).","journal-title":"Oncogene"},{"key":"502_CR34","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","volume":"114","author":"G Yoshimoto","year":"2009","unstructured":"Yoshimoto, G. et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 114, 5034\u20135043 (2009).","journal-title":"Blood"},{"key":"502_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2015.08.003","volume":"43","author":"AL Hsieh","year":"2015","unstructured":"Hsieh, A. L., Walton, Z. E., Altman, B. J., Stine, Z. E. & Dang, C. V. MYC and metabolism on the path to cancer. Semin. Cell Dev Biol. 43, 11\u201321 (2015).","journal-title":"Semin. Cell Dev Biol."},{"key":"502_CR36","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","volume":"5","author":"ZE Stine","year":"2015","unstructured":"Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L. & Dang, C. V. MYC, metabolism, and cancer. Cancer Discov. 5, 1024\u20131039 (2015).","journal-title":"Cancer Discov."},{"key":"502_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fendo.2018.00129","volume":"9","author":"ES Goetzman","year":"2018","unstructured":"Goetzman, E. S. & Prochownik, E. V. The role for Myc in coordinating glycolysis, oxidative phosphorylation, glutaminolysis, and fatty acid metabolism in normal and neoplastic tissues. Front. Endocrinol. 9, 129 (2018).","journal-title":"Front. Endocrinol."},{"key":"502_CR38","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature07823","volume":"458","author":"P Gao","year":"2009","unstructured":"Gao, P. et al. c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762\u2013765 (2009).","journal-title":"Nature"},{"key":"502_CR39","doi-asserted-by":"publisher","first-page":"18782","DOI":"10.1073\/pnas.0810199105","volume":"105","author":"DR Wise","year":"2008","unstructured":"Wise, D. R. et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl Acad. Sci. USA 105, 18782\u201318787 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"502_CR40","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/leu.2010.114","volume":"24","author":"M Buchwald","year":"2010","unstructured":"Buchwald, M. et al. Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation. Leukemia 24, 1412\u20131421 (2010).","journal-title":"Leukemia"},{"key":"502_CR41","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1158\/1078-0432.CCR-04-0210","volume":"10","author":"P Bali","year":"2004","unstructured":"Bali, P. et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin. Cancer Res. 10, 4991\u20134997 (2004).","journal-title":"Clin. Cancer Res."},{"key":"502_CR42","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.leukres.2008.02.018","volume":"32","author":"C Nishioka","year":"2008","unstructured":"Nishioka, C. et al. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk. Res. 32, 1382\u20131392 (2008).","journal-title":"Leuk. Res."},{"key":"502_CR43","doi-asserted-by":"publisher","first-page":"1000166","DOI":"10.4172\/2576-1471.1000166","volume":"2","author":"KA Minson","year":"2017","unstructured":"Minson, K. A., DeRyckere, D. & Graham, D. K. The current state of FLT3 inhibition in acute myeloid leukemia\u2014pitfalls and promises. J. Cell Signal. 2, 1000166 (2017).","journal-title":"J. Cell Signal."},{"key":"502_CR44","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","volume":"76","author":"E Traer","year":"2016","unstructured":"Traer, E. et al. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Res. 76, 6471\u20136482 (2016).","journal-title":"Cancer Res."},{"key":"502_CR45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bjh.12599","volume":"164","author":"X Yang","year":"2014","unstructured":"Yang, X., Sexauer, A. & Levis, M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br. J. Haematol. 164, 61\u201372 (2014).","journal-title":"Br. J. Haematol."},{"key":"502_CR46","doi-asserted-by":"publisher","first-page":"8870","DOI":"10.18632\/oncotarget.22926","volume":"9","author":"K Okada","year":"2018","unstructured":"Okada, K. et al. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K\/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1\/Mcl-1 pathway. Oncotarget. 9, 8870\u20138886 (2018).","journal-title":"Oncotarget."},{"key":"502_CR47","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/leu.2011.46","volume":"25","author":"AM Martelli","year":"2011","unstructured":"Martelli, A. M. et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K\/PTEN\/Akt\/mTOR pathway. Leukemia 25, 1064\u20131079 (2011).","journal-title":"Leukemia"},{"key":"502_CR48","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/sj.leu.2404760","volume":"21","author":"S Inoue","year":"2007","unstructured":"Inoue, S., Riley, J., Gant, T. W., Dyer, M. J. S. & Cohen, G. M. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 21, 1773\u20131782 (2007).","journal-title":"Leukemia"},{"key":"502_CR49","doi-asserted-by":"publisher","first-page":"6149","DOI":"10.1128\/MCB.01481-08","volume":"29","author":"S Chen","year":"2009","unstructured":"Chen, S., Dai, Y., Pei, X. Y. & Grant, S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-x(L), and Mcl-1. Mol. Cell Biol. 29, 6149\u20136169 (2009).","journal-title":"Mol. Cell Biol."},{"key":"502_CR50","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1128\/MCB.25.14.6225-6234.2005","volume":"25","author":"F Li","year":"2005","unstructured":"Li, F. et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell Biol. 25, 6225\u20136234 (2005).","journal-title":"Mol. Cell Biol."},{"key":"502_CR51","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1182\/blood-2017-12-820035","volume":"131","author":"P Gallipoli","year":"2018","unstructured":"Gallipoli, P. et al. Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood 131, 1639\u20131653 (2018).","journal-title":"Blood"},{"key":"502_CR52","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes, A. et al. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 17, 622\u2013631 (2016).","journal-title":"Lancet Oncol."},{"key":"502_CR53","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.3324\/haematol.2017.172882","volume":"102","author":"Y Oki","year":"2017","unstructured":"Oki, Y. et al. CUDC-907 in relapsed\/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica 102, 1923\u20131930 (2017).","journal-title":"Haematologica"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00502-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:45:59Z","timestamp":1669909559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00502-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00502-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"2 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"111"}}